TG Therapeutics Incorporated (NASDAQ:TGTX) Just Reported Increased Shorts

August 16, 2017 – By Marie Mckinney

Investors sentiment increased to 2.35 in 2016 Q4. Its up 1.68, from 0.67 in 2016Q3. It is positive, as 5 investors sold TG Therapeutics Inc shares while 15 reduced holdings. 16 funds opened positions while 31 raised stakes. 21.26 million shares or 20.65% less from 26.79 million shares in 2016Q3 were reported.
Swiss National Bank & Trust holds 0% or 66,600 shares. Teachers Retirement System Of The State Of Kentucky stated it has 0.01% of its portfolio in TG Therapeutics Inc (NASDAQ:TGTX). National Bank Of America Corp De holds 0% in TG Therapeutics Inc (NASDAQ:TGTX) or 12,681 shares. Pub Employees Retirement Association Of Colorado invested 0% of its portfolio in TG Therapeutics Inc (NASDAQ:TGTX). Amer Intll Gp Inc holds 0% of its portfolio in TG Therapeutics Inc (NASDAQ:TGTX) for 21,181 shares. Art Advsr Limited Liability Corp has invested 0.02% in TG Therapeutics Inc (NASDAQ:TGTX). Point72 Asia (Hong Kong) has invested 0.02% of its portfolio in TG Therapeutics Inc (NASDAQ:TGTX). New York State Common Retirement Fund stated it has 223,851 shares. Raymond James Services Advsr reported 30,838 shares or 0% of all its holdings. Moreover, Alliancebernstein L P has 0% invested in TG Therapeutics Inc (NASDAQ:TGTX) for 60,940 shares. Michigan-based Plante Moran Financial Advsr Ltd Llc has invested 0% in TG Therapeutics Inc (NASDAQ:TGTX). Jpmorgan Chase Com accumulated 35,146 shares or 0% of the stock. Vanguard Group has invested 0% in TG Therapeutics Inc (NASDAQ:TGTX). Blackrock Inv Ltd Company reported 146,838 shares. Wells Fargo And Mn reported 131,268 shares or 0% of all its holdings.

Since April 4, 2017, it had 0 insider buys, and 3 selling transactions for $831,111 activity. Charney Laurence N sold $78,190 worth of TG Therapeutics Inc (NASDAQ:TGTX) on Tuesday, April 4. $665,133 worth of TG Therapeutics Inc (NASDAQ:TGTX) was sold by Power Sean A on Friday, June 16. $87,788 worth of TG Therapeutics Inc (NASDAQ:TGTX) shares were sold by KENNEDY WILLIAM JAMES.

The stock of TG Therapeutics Incorporated (NASDAQ:TGTX) registered an increase of 1.8% in short interest. TGTX’s total short interest was 14.68M shares in August as published by FINRA. Its up 1.8% from 14.42 million shares, reported previously. With 2.63M shares average volume, it will take short sellers 6 days to cover their TGTX’s short positions. The short interest to TG Therapeutics Incorporated’s float is 43.73%.

About 243,175 shares traded. TG Therapeutics Inc (NASDAQ:TGTX) has risen 60.54% since August 16, 2016 and is uptrending. It has outperformed by 43.84% the S&P500.

TG Therapeutics, Inc. is a biopharmaceutical firm focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. The company has market cap of $786.45 million. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. It currently has negative earnings. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.

TG Therapeutics Inc (NASDAQ:TGTX) Ratings Coverage

Among 7 analysts covering TG Therapeutics (NASDAQ:TGTX), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. TG Therapeutics had 10 analyst reports since August 12, 2015 according to SRatingsIntel. The stock has “Buy” rating by Jefferies on Monday, June 5. The stock of TG Therapeutics Inc (NASDAQ:TGTX) has “Buy” rating given on Wednesday, August 12 by H.C. Wainwright. The stock has “Hold” rating by Zacks on Wednesday, August 12. The rating was initiated by FBR Capital on Tuesday, December 1 with “Outperform”. The company was maintained on Thursday, June 15 by FBR Capital. The stock has “Strong Buy” rating by Raymond James on Wednesday, September 9. The stock of TG Therapeutics Inc (NASDAQ:TGTX) earned “Buy” rating by SunTrust on Friday, May 27. H.C. Wainwright maintained it with “Buy” rating and $18 target in Tuesday, March 7 report. Brean Capital reinitiated the stock with “Buy” rating in Thursday, October 6 report. Suntrust Robinson initiated the stock with “Buy” rating in Friday, May 27 report.

More notable recent TG Therapeutics Inc (NASDAQ:TGTX) news were published by: Globenewswire.com which released: “TG Therapeutics Announces Special Protocol Assessment (SPA) Agreement with the …” on August 01, 2017, also Fool.com with their article: “What’s Behind TG Therapeutics Inc.’s 14.4% Rally in July?” published on August 07, 2017, Globenewswire.com published: “TG Therapeutics, Inc. Announces Successful Outcome from the First Pre-Planned …” on August 10, 2017. More interesting news about TG Therapeutics Inc (NASDAQ:TGTX) were released by: Seekingalpha.com and their article: “TG Therapeutics’ (TGTX) CEO Mike Weiss on Q2 2017 Results – Earnings Call …” published on August 12, 2017 as well as Nasdaq.com‘s news article titled: “TG Therapeutics, Inc. Provides Business Update and Reports Second Quarter 2017 …” with publication date: August 09, 2017.